{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115418","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.287301+00:00","generated_at":"2026-06-22T05:05:47.374089+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cara Q3 net loss $23.2M; KORSUVA revenue $16.2M, 180K vials shipped","bullets":["Net loss $23.2M ($0.43/share) vs $1.0M loss ($0.02) in Q3 2021; total revenue $10.8M down from $20.3M.","KORSUVA injection net sales $16.2M incl. $7.4M profit-share from Vifor; ~180K vials shipped to dialysis centers.","Discontinued Phase 2 PBC trial due to slow enrollment; FDA meeting in 4Q22 to discuss NP pivotal program.","Cash $179.5M at Sept 30, 2022 (Dec 2021: $236.8M); expects to fund ops into first half 2024.","Appointed Ryan Maynard as CFO and Lisa von Moltke to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115418","json":"https://secwatch.observer/filing/0001104659-22-115418.json","markdown":"https://secwatch.observer/filing/0001104659-22-115418.md","text":"https://secwatch.observer/filing/0001104659-22-115418.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922115418/0001104659-22-115418-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922115418/tm2229821d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:05:47.374089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51f172cbae2c58d5542fa359dc4c16102b2fa61b","claim":"Tvardi Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $16.2M.","evidence_excerpt":"Cara Therapeutics Reports Third Quarter 2022 Financial Results – Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922115418/0001104659-22-115418-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$16.2M"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}